Objectives: As most available antimalarial drugs are ineffective against the Plasmodium falciparum transmission stages, new drugs against the parasite's gametocytes are urgently needed to combat malaria globally. The unique biology of gametocytes requires assays that need to be specific, to faithfully monitor anti-gametocyte activity, and to be easy to perform, cheap and scalable to high-throughput screening (HTS). Methods:We developed an HTS cell-based assay with P. falciparum gametocytes specifically expressing a potent luciferase. To confirm HTS hit activity for several parasite genotypes, the luciferase assay and the gametocyte lactate dehydrogenase (LDH) assay, usable on any parasite isolate, were compared by screening antimalarial drugs and determining IC50 values of anti-gametocyte hits from the 'Malaria Box' against early- and latestage gametocytes. Results: Comparison of the two assays, conducted on the early and on late gametocyte stages, revealed an excellent correlation (R2.0.9) for the IC50 values obtained by the respective readouts. Differences in susceptibility to drugs and compounds between the two parasite developmental stages were consistently measured in both assays. Conclusions: This work indicates that the luciferase and gametocyte LDH assays are interchangeable and that their specific advantages can be exploited to design an HTS pipeline leading to new transmission-blocking compounds. Results from these assays consistently defined a gametocyte chemical susceptibility profile, relevant to the planning of future drug discovery strategies.
A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays / S. D'Alessandro, G. Camarda, Y. Corbett, G. Siciliano, S. Parapini, L. Cevenini, E. Michelini, A. Roda, D. Leroy, D. Taramelli, P. Alano. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 71:5(2016 May), pp. dkv493.1148-dkv493.1158. [10.1093/jac/dkv493]
A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays
S. D'AlessandroPrimo
;Y. Corbett;S. Parapini;D. TaramelliPenultimo
;
2016
Abstract
Objectives: As most available antimalarial drugs are ineffective against the Plasmodium falciparum transmission stages, new drugs against the parasite's gametocytes are urgently needed to combat malaria globally. The unique biology of gametocytes requires assays that need to be specific, to faithfully monitor anti-gametocyte activity, and to be easy to perform, cheap and scalable to high-throughput screening (HTS). Methods:We developed an HTS cell-based assay with P. falciparum gametocytes specifically expressing a potent luciferase. To confirm HTS hit activity for several parasite genotypes, the luciferase assay and the gametocyte lactate dehydrogenase (LDH) assay, usable on any parasite isolate, were compared by screening antimalarial drugs and determining IC50 values of anti-gametocyte hits from the 'Malaria Box' against early- and latestage gametocytes. Results: Comparison of the two assays, conducted on the early and on late gametocyte stages, revealed an excellent correlation (R2.0.9) for the IC50 values obtained by the respective readouts. Differences in susceptibility to drugs and compounds between the two parasite developmental stages were consistently measured in both assays. Conclusions: This work indicates that the luciferase and gametocyte LDH assays are interchangeable and that their specific advantages can be exploited to design an HTS pipeline leading to new transmission-blocking compounds. Results from these assays consistently defined a gametocyte chemical susceptibility profile, relevant to the planning of future drug discovery strategies.File | Dimensione | Formato | |
---|---|---|---|
J. Antimicrob. Chemother.-2016-D'Alessandro-jac-dkv493.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
583.85 kB
Formato
Adobe PDF
|
583.85 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.